This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

TIDES USA: Oligonucleotide & Peptide Therapeutics

Early Savings Deadline Expires In:

  • 00
  • 00
  • 00
  • 00
Delivered as a Hybrid Event
May 9-12, 2022 | In-Person + DigitalHynes Convention Center, Boston

Stephen Spagnol, PhD
Associate Director, Biotherapeutics Development at Janssen R&D


Stephen Spagnol received his B.S. in Chemical Engineering from Penn State in 2010, and went on to receive his Ph.D. in Chemical Engineering from Carnegie Mellon in 2015. He started his career at Merck & Co. in 2015 in Pharmaceutical Sciences. While at Merck, he led formulation and process development efforts in RNA therapeutics including vaccines and novel therapeutics in immuno-oncology. He also has extensive experience in the design and optimization of novel drug delivery technologies for RNA therapeutics. He recently joined Johnson & Johnson where he is Associate Director, Janssen R&D

Agenda Sessions

  • Chairman’s Remarks: Novel Drug Delivery Technologies for Macromolecules